Article info
PDFLetter
BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept
- Correspondence to Dr Lingli Dong, Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; tjhdongll{at}163.com; Dr Jixin Zhong, Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; zhongjixin620{at}163.com; Dr Cong Ye, Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; yecong2011{at}163.com
Citation
BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept
Publication history
- Received October 25, 2022
- Accepted January 6, 2023
- First published January 19, 2023.
Online issue publication
October 18, 2023
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.